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Introduction. Studies have shown that T2DM is an inflammatory disease. Thus, the present study was aimed at evaluating whether
diacerein could improve the metabolic and inflammatory profile among patients with T2DM under long-term treatment with
glucose-lowering agents. Methods. This is a double-blind, parallel, placebo-controlled trial with 72 participants randomly
assigned to diacerein 50mg or placebo for 12 weeks. The primary endpoint was the between-group difference in change in
HbA1c. Secondary endpoints included the proportion of patients achieving metabolic control [HbA1c ≤ 7 0% (53mmol/mol)]
and change in inflammatory mediators. Results. Participants in the diacerein group had greater reductions in mean HbA1c level
in comparison to placebo (−0.98; 95% CI: −2.02 to 0.05, P = 0 06), independently of confounding factors. The difference in
HbA1c level was −1.3 (95% CI: −2.3 to −0.4) in favor of diacerein (P = 0 007) in those with <14 years of diabetes duration
versus 0.05 (−0.7 to 0.8; P = 0 9) in those with longer duration. The diacerein group had a 50% increase in the number of
participants at the lowest TNF-α level (≤1.46 pg/mL). Conclusions. In patients with long-established T2DM under long-term
treatment with glucose-lowering agents, diacerein improves metabolic control as measured by HbA1c level and has a favorable
impact on inflammatory profile. Clinical Trial Registry. This trial is registered with Brazilian Clinical Trials Registry (ReBEC)
number RBR-29j956.
1. Introduction
Type 2 diabetes mellitus (T2DM) and obesity-related insulin
resistance (IR) have been involved in a state of low-grade
chronic inflammation and activation of the immune system
[1]. The size of adipocytes might play a role in IR and
lipolytic activity, since larger ones release less adiponectin
and more inflammatory cytokines [2]. The immune changes
that occur in diabetes—changes in the number and activa-
tion state of leukocyte populations, increased apoptosis
and tissue fibrosis, abnormal cytokine production, elevated
levels of acute-phase proteins, and other mediators—have
been shown to activate inflammatory pathways [3–5].
Inflammation is related to insulin resistance, which increases
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pancreatic islet cell mass and insulin secretory activity until
insulin deficiency develops [4, 6].
Several mechanisms contribute to beta-cell dysfunction
and insulin resistance in T2DM. These mechanisms are
strongly interlinked and contribute to tissue inflammation.
The main dysfunctions affecting beta cells are glucotoxicity,
lipotoxicity, oxidative stress, and amyloid deposition. All lead
to activation of the immune system in adipose tissues, liver,
pancreatic islets, the vasculature, and leukocytes. Immune
adaptations alter levels of cytokines and chemokines, activate
leukocyte populations, and increase apoptosis and tissue
fibrosis [4].
The inflammatory pathway of T2DM has led to the
investigation of drugs that act at different points of the
inflammatory orbit. Anti-inflammatory treatment appears
to improve insulin sensitivity and glycemic control in
insulin-resistant patients with T2DM or inflammatory con-
ditions [7]. In addition, glucose-lowering agents have been
associated with anti-inflammatory effects, although it is
not known whether this results from better glucose control
or their intrinsic pharmacological effect [8]. Recent trials
[9–11] of the anti-inflammatory agent diacerein conducted
in patients with T2DM have shown improvement on meta-
bolic control in both drug-naïve patients [9] and those under
glucose-lowering therapy [10, 11]. Furthermore, diacerein
seems to slow deterioration of metabolic control in patients
with T2DM and chronic kidney disease [12].
However, most of these studies enrolled T2DM patients
within a limited range of age and diabetes duration. In
addition, there are few studies assessing the impact of dia-
cerein on the metabolic and anti-inflammatory profile
among patients with established disease undergoing long-
term treatment, including with insulin. Within this context,
the present study was aimed at evaluating whether diacer-
ein could improve the metabolic and inflammatory profile
of patients with T2DM under long-term treatment with
glucose-lowering agents.
2. Materials and Methods
Patients with T2DM were recruited from the outpatient
diabetes clinic of a university hospital in Passo Fundo,
Southern Brazil. This randomized, double-blind, parallel,
placebo-controlled trial enrolled participants aged 34 to
79 years, who had glycated hemoglobin HbA1c ≥ 7 4%
(57.4mmol/mol) and <11.0% (97mmol/mol) and did not
have kidney disease. Exclusion criteria included pregnancy,
chronic inflammatory diseases such as rheumatoid arthritis
and osteoarthritis, use of anti-inflammatory agents for more
than five days in the last three months, previous diagnosis of
pancreatitis, hypersensitivity to rhein and anthraquinone
derivatives, liver disease (transaminases > 2 5 times the
upper limit of normal), severe gastrointestinal disease/
persistent diarrhea, signs of intercurrent infection, participa-
tion in another randomized controlled trial in the last 30
days, or inability to follow the protocol.
The protocol was registered into the Plataforma Brasil
clinical trial registry as a precondition for Ethics Committee
submission. It was approved by the Ethics Committee of
Hospital de Clínicas de Porto Alegre (GPPG number
120482, on December 17, 2012), which is accredited by the
US Office of Human Research Protections as an Institutional
Review Board. The trial was subsequently registered in
the Brazilian Clinical Trials Registry platform (available at
http://www.ensaiosclinicos.gov.br/rg/RBR-29j956). Written
informed consent was obtained from all participants, accord-
ing to the principles expressed in the Declaration of Helsinki.
This trial was designed, implemented, and described follow-
ing the provisions of the CONSORT statement.
Participants were randomly assigned in a 1 : 1 ratio to
receive either diacerein 50mg or placebo, twice daily for 12
weeks. The randomization sequence was generated by a
web-based randomization software (Random Allocation
Software) with permuted-block allocation, with block sizes
of four and six. This was done before the start of the trial
by an epidemiologist not involved with clinical procedures.
Diacerein and placebo capsules, identical in appearance, were
stored in bottles labeled using an alphanumeric code. The
bottles were stored out of the clinical site, with access con-
trolled by a research assistant. After confirmation of eligibil-
ity, each participant received a bottle, ensuring allocation
concealment and blinding of intervention to participants,
care providers, and those assessing outcomes. Diacerein
and placebo were manufactured by a pharmaceutical com-
pany (TRB Pharma, Campinas, SP, Brazil). Participants were
asked to return for follow-up visits on days 7, 30, 60, and
90 after randomization to verify adherence to treatment
and monitor adverse events. Patients in both groups were
instructed to maintain their prescribed glucose-lowering
agents and dietary recommendations. Adherence to treat-
ment was self-reported and measured by counting the num-
ber of pills that were returned at each visit. The trial ended on
day 90, when baseline measures were repeated.
The primary endpoint was the difference in change in
HbA1c (end of trial minus baseline level), between the
placebo and diacerein groups. Secondary endpoints included
the proportion of patients achieving metabolic control
[HbA1c ≤ 7 0% (53mmol/mol)] and the difference between
the two treatment arms in plasma levels of fasting glucose
(mg/dL), inflammatory mediators [IL-1β, tumor necrosis
factor- (TNF-) α, IL-6, and IL-10], and lipids [high-density
lipoprotein cholesterol (HDLc), low-density lipoprotein cho-
lesterol (LDLc), total cholesterol (TC), and triglycerides
(TGs)], homeostasis model assessment of insulin resistance
(HOMA1-IR), and rate of adverse events. Blood samples
were collected after a 12-hour fast by venipuncture from
all participants at baseline and at the end of the study.
The samples were centrifuged and aliquoted for later anal-
ysis. Interleukin levels were measured using a customized
Luminex® Human Ultrasensitive magnetic bead panel. Fast-
ing glucose was measured by an enzymatic and colorimetric
method and HbA1c by immunoturbidimetric assay.
The assessment included anthropometric measures,
24-hour ambulatory blood pressure monitoring (ABPM),
use of statins, and blood pressure-lowering agents. Changes
in the dose of glucose-lowering agents were collected in order
to identify cointerventions that could affect the efficacy of
the study intervention. Hypertension was defined as office
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systolic blood pressure SBP ≥ 140mmHg or diastolic blood
pressure DBP ≥ 90mmHg or current treatment with blood
pressure-lowering agents.
2.1. Sample Size Calculation and Statistical Analysis. A sam-
ple size of 31 participants in each group was estimated to
detect a difference of 1.0% (SD± 1.5) in HbA1c between
diacerein and placebo arms, assuming a two-tailed test with
significance of 0.05 and power of 80%. To account for possi-
ble losses to follow-up during the trial, 36 participants were
included in each group. Outcomes were analyzed following
the intention-to-treat approach.
Characteristics of the sample were compared between
the two groups using Student’s t-test for continuous vari-
ables or Pearson’s chi-square test for categorical variables.
A general linear model for baseline and end-of-trial mea-
sures was applied to analyze the effect of diacerein, and
the change from baseline was estimated using analysis of
covariance (ANCOVA) with control of baseline values for
age, gender, diabetes duration, and change in dosage of
glucose-lowering agents during the trial. P values < 0 05 were
considered statistically significant. Because of the wide range
of diabetes duration, analysis of HbA1c was stratified by
diabetes duration (1–13 and 14–30 years) to explore the effect
of diacerein in long-established diabetes mellitus. The levels
of HbA1c were adjusted for gender and age. Considering
the nonnormal distribution of inflammatory markers, they
were categorized at the 25th or 75th percentile for baseline
and end-of-trial values. The baseline 25th percentile was
defined as the cutoff point for IL-6, IL-8, IL-10, leptin, selec-
tin, and adiponectin, as well as the 75th percentile for IL-1β.
For TNF-α, the 50th percentile (or median) baseline value
was defined as the cutoff point. Poisson regression with a
robust estimator was performed to verify the effect of
diacerein on inflammatory markers, using the values at the
end of the trial as outcomes and adjusting for baseline values.
Relative risk and 95% CIs were used to express the associa-
tion. All analyses were performed using SPSS for Windows
(version 17.0; SPSS Inc., Chicago, IL, USA).
3. Results
Among 85 patients with T2DM assessed for eligibility,
72 were enrolled in the trial (36 in each group) and
71 completed the study. Participants attended all scheduled
visits, but one participant in the diacerein group moved to
another city and did not complete the baseline assessment
(Figure 1). The trial was conducted from September 2013 to
March 2014.
The baseline characteristics of the participants are shown
in Table 1. The mean (SD) age was 62 (8) years in the diacer-
ein group versus 59 (11) years in the placebo group. In both
groups, participants, on average, completed six years of
formal education, were obese, and had long-established
diabetes, hypertension, and well-controlled blood pressure
on 24-hour ABPM. Participants in the diacerein group were,
on average, older, women, and with higher HbA1c levels, but
used metformin less often than those who were taking
placebo. About half of all participants were using insulin.
Self-reported adherence to the study drug was high in both
groups (diacerein, 93.7%± 14.3; placebo, 92.7%± 14.8), as
well as pill counting, with 88.6% of diacerein-treated patients
versus 86% of placebo-treated patients reporting 90% or
more intake of the capsules. Although patients were advised
to continue their glucose-lowering treatment as at baseline,
one patient in the diacerein group and four in the placebo



































Figure 1: Flow diagram of participant selection, randomization, and follow-up.
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Table 2 shows that participants in the diacerein group
had greater reduction in mean HbA1c level compared to
the placebo arm, independently of age, gender, duration of
diabetes, and addition of a new antidiabetic drug. The
adjusted difference in mean change (−0.98; 95% CI: −2.02
to 0.05) had a P value of 0.06. As shown on exploratory
analysis (Figure 2), the most striking reduction in glycated
hemoglobin was observed among participants in the diacer-
ein group who had shorter duration of diabetes mellitus.
The difference in HbA1c level was −1.3 (95% CI: −2.3 to
−0.4) in favor of diacerein (P = 0 007) in the <14 years of
diabetes duration versus 0.05 (−0.7 to 0.8), with P = 0 9, in
Table 1: Baseline characteristics of participants randomized to diacerein and placebo.
Characteristics Diacerein (n = 35) Placebo (n = 36) P value
Age (years) 62± 8.0 59± 11.3 0.12
Male 20 (57.1) 27 (75.0) 0.11
Years at school 6.4± 4.1 5.6± 3.0 0.4
Chronic complications of diabetes 18 (51.4) 13 (36.1) 0.19
Cardiovascular disease 14 (40.0) 13 (36.1) 0.7
Hypertension 29 (82.9) 31 (86.1) 0.7
24 h systolic blood pressure (mmHg) 120.3± 11.5 123.1± 11.4 0.7
24 h diastolic blood pressure (mmHg) 75.0± 8.4 72.3± 8.1 0.3
Duration of diabetes (years) 14.0± 6.7 14.8± 6.6 0.7
Duration of diabetes 14–30 years 19 (54.3) 23 (63.9) 0.4
Use of oral hypoglycemic agents‡
Sulfonylureas 13 (37.1) 12 (33.3) 0.7
Metformin 25 (71.4) 31 (86.1) 0.13
Use of insulin 17 (48.6) 22 (61.1) 0.3
Use of other antidiabetics# 1 (2.9) 4 (11.1) 0.17
Metabolic profile
HbA1c (%) 9.1± 1.4 8.6± 1.0 0.11
HbA1c (mmol/mol) 76.7± 2.4 71.2± 2.4 0.11
Fasting glucose (mg/dL) 142.0± 69.5 138.7± 58.2 0.8
HOMA-IR 5.4± 1.0 6.5± 1.0 0.4
Lipids
Total cholesterol (mg/dL) 149± 32.7 152.7± 34.8 0.6
HDLc (mg/dL) 42.1± 7.4 42.8± 8.0 0.7
LDLc (mg/dL) 73.0± 35.6 78.5± 35.5 0.3
Triglycerides (mg/dL) 200.5± 124.4 202.4± 210.5 1.0
Renal
Creatinine (mg/dL) 0.93± 0.15 0.87± 0.17 0.11
eGFR (mL/min/1.73m2) 77.0± 13.1 83.5± 23.5 0.13
Urinary albumin/creatinine ratio (mg/24 h) 9.9± 6.6 10.8± 6.8 0.6
Hepatic
ALT (units/L) 23.5± 11.1 23.1± 11.3 0.9
AST (units/L) 24.7± 11.8 21.9± 8.1 0.2
Gamma-glutamyltransferase (units/L) 43.4± 26.4 36.1± 20.6 0.2
Hematologic/inflammatory
Hematocrit (%) 42.0± 4.9 41.7± 4.3 0.8
Platelet count (×109 cells/L) 215.0± 55.7 221.8± 60.0 0.6
C-reactive protein (mg/L) 7.0± 6.2 9.0± 16.4 0.5
Anthropometric assessment
Weight (kg) 80.3± 19.8 78.7± 13.1 0.7
Height (m) 1.62± 0.10 1.59± 0.07 0.16
Body mass index (kg/m2) 30.8± 6.9 31.3± 5.2 0.7
Data expressed as mean ± SD and n (%). ‡Numbers exceed 100% due to use of more than one agent. #Alpha-glucosidase inhibitors, meglitinides, DPP4
inhibitors, and amylin mimetics.
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the 14–30 years in the diabetes duration group. Assessment
of HbA1c at baseline and at the end of the trial for each
treatment group showed that, in the subgroup with longer
duration of diabetes, there was a crude reduction of one per-
centage point in both the diacerein (9.6± 1.7 to 8.7± 1.5)
and placebo (8.7± 1.1 to 7.7± 1.3) groups. In the subgroup
with <14 years of diabetes duration, diacerein reduced
HbA1c by one percentage point (8.7± 1.0 to 7.6± 1.3), with
no appreciable change in the placebo group (8.6± 1.1 to
8.9± 1.3). Figure 2 shows that both groups of patients,
independent of duration of T2DM, had HbA1c levels
decreased by about one percentage point at the end of
the trial; in the shorter T2DM duration subgroup, the
placebo group exhibited a noticeable increase in HbA1c,
while in the longer T2DM duration subgroup, there had
been a reduction of approximately one percentage point,
independently of gender and age. Plotting diabetes dura-
tion against HbA1C yielded a Spearman correlation coef-
ficient of 0.42 (P = 0 01) for the diacerein group and 0.27
(P = 0 12) for the placebo group.
There were no statistically significant differences between
groups in fasting glucose, HOMA-IR, and serum lipid levels;
renal, hepatic, hematological, and inflammatory parameters;
or anthropometric assessment (Table 2).
The results of the inflammatory markers are shown in
Table 3. The diacerein group had a 50% increase in the num-
ber of participants at the lowest level of TNF-α (≤1.46 pg/mL)
at the end of the trial, independently of baseline values.
Adjusting for confounding factors (the same variables
described in Table 2) did not change this result.
Table 4 shows a similar distribution of adverse effects
between diacerein and placebo, except for a higher frequency
of dark urine in the former. Five other symptoms, including
diarrhea and nausea, were more often reported by partici-
pants in the diacerein group, but there was no drug-related
discontinuation of treatment.
4. Discussion
This randomized controlled trial assessed the effect of
diacerein (versus placebo) as an adjunctive agent in the
treatment of T2DM in patients receiving antidiabetic
drugs. Diacerein was able to reduce HbA1c in comparison
to placebo (P = 0 06), but the difference became statistically
Table 2: Mean values during the 12-week treatment and adjusted differences in mean changes between diacerein and placebo for the trial
outcomes (mean ± SE).











HbA1c (%) 8.1± 0.2 −0.98± 0.2 8.1± 0.2 −0.52± 0.2 −0.98 (−2.02 to 0.05) 0.06
HbA1c (mmol/mol) 65.9± 2.6 −10.8± 2.4 65.5± 2.6 −5.7± 2.3 −10.8 (−22.0 to 0.5) 0.06
Fasting glucose (mg/dL) 146.3± 13.1 4.3± 11.9 150.4± 12.9 11.8± 11.8 −19.8 (−78.3 to 38.5) 0.5
HOMA-IR 5.3± 0.8 −0.18± 0.7 6.2± 0.8 −0.27± 0.7 1.0 (−2.6 to 4.6) 0.6
Lipids
Total cholesterol (mg/dL) 148.7± 5.5 −0.3± 4.6 151.1± 5.2 −1.6± 4.5 −0.12 (−22.9 to 22.6) 1.0
HDLc (mg/dL) 41.3± 1.3 −0.8± 0.9 42.8± 6.9 −0.03± 0.8 −2.2 (−6.4 to 2.1) 0.3
LDLc (mg/dL) 79.9± 5.1 6.8± 6.1 78.2± 5.0 −3.2± 6.0 20.1 (−10.4 to 50.5) 0.19
Triglycerides (mg/dL) 153.1± 17.7 −47.4± 23.2 164.7± 17.4 −37.7± 22.9 −78.7 (−193.4 to 36.1) 0.18
Renal
Creatinine (mg/dL) 1.0± 0.04 0.06± 0.03 1.0± 0.04 0.03± 0.03 0.12 (−0.03 to 0.26) 0.11
eGFR (mL/min/1.73m2) 73.9± 3.2 −3.1± 1.9 81.7± 3.2 −1.8± 1.9 −7.7 (−17.3 to 1.9) 0.12
Urinary albumin/creatinine ratio (mg/24 h) 24.0± 5.6 14.1± 5.2 27.3± 5.5 16.5± 5.2 6.0 (−19.4 to 31.4) 0.6
Hepatic
ALT (units/L) 24.4± 2.4 0.9± 1.6 25.1± 2.4 2.0± 1.5 0.5 (−6.5 to 7.5) 0.8
AST (units/L) 27.1± 2.3 2.4± 1.5 26.2± 2.3 4.3± 1.5 −0.6 (−8.0 to 6.8) 0.9
Gamma-glutamyltransferase (units/L) 44.9± 4.9 1.5± 2.4 39.3± 4.8 3.2± 2.3 −7.7 (−19.3 to 4.0) 0.19
Hematologic/inflammatory
Hematocrit (%) 42.7± 0.8 0.8± 0.8 43.4± 0.8 1.7± 0.8 0.5 (−3.6 to 4.5) 0.8
Platelet count (×109 cells/L) 230± 10.2 15.03± 7.3 236± 10.0 14.6± 7.2 −5.1 (−41.6 to 31.4) 0.8
C-reactive protein (mg/L) 9.0± 2.5 2.0± 3.3 12.3± 2.5 3.3± 3.2 −9.8 (−25.3 to 5.7) 0.2
Anthropometric assessment
Weight (kg) 77.6± 2.6 −2.7± 0.7 77.3± 2.6 −1.4± 0.7 −2.4 (−5.6 to 0.9) 0.16
Body mass index (kg/m2) 29.8± 1.0 −1.0± 0.2 30.8± 1.0 −0.6± 0.2 −0.8 (−2.0 to 0.4) 0.19
∗Mean adjusted for age, gender, duration of diabetes, and addition of new antidiabetic drugs.
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significant for participants who had shorter duration of dia-
betes mellitus. Among participants with long-established
T2DM, diacerein and placebo both reduced the HbA1c
levels; therefore, there was no effect [0.05 (95% CI: −0.7 to
0.8)]. On the other hand, in participants with shorter dura-
tion of diabetes, diacerein was associated with one percent-
age point reduction, while in the placebo group, there was
a noticeable increase in HbA1C level after controlling for
age and gender. The effect toward better control of diabetes
is consistent with the decrease in TNF-α level observed in
the diacerein group at the end of the trial. Diacerein
reduced the proportion of participants with abnormal levels
comparatively to the placebo group, as detected by a 50%
increase in the number of participants who migrated to
the lowest percentile.
This trial was carried out in T2DM patients with long-
established disease and undergoing long-term treatment with
metformin, sulfonylureas, or insulin. In two previous studies
[9, 10], diacerein was evaluated in small samples, among
T2DM patients under the age of 60, who were drug-
naïve or receiving metformin as monotherapy for diabetes.
Ramos-Zavala et al. [9] evaluated the efficacy of diacerein
in 40 drug-naïve patients with newly diagnosed T2DM
and HbA1c levels between 7% (53mmol/mol) and 9%
(75mmol/mol) and found a significant absolute reduction
of 1.3% (14.2mmol/mol) in HbA1c as well as in TNF-α and
Table 3: Effect of diacerein on inflammatory markers at end of trial.
Diacerein (n = 35) Placebo (n = 36) RR (95% CI)∗ P value
α − Tumor necrosis factor ≤ 1 46 (pg/mL) 23 (65.7) 14 (38.9) 1 (1.04–2.1) 0.03
Interleukin − 1β > 1 23 8 (22.9) 15 (41.7) 0.7 (0.4–1.3) 0.3
Interleukin − 6 ≤ 10 7 17 (48.6) 14 (38.9) 1.4 (0.9–2.2) 0.19
Interleukin − 8 ≤ 29 53 6 (17.1) 2 (5.6) 3.1 (0.7–14.8) 0.15
Interleukin − 10 ≤ 5 25 10 (28.6) 5 (13.9) 1.8 (0.7–4.6) 0.19
Leptin ≤ 10 3 11 (31.4) 6 (16.7) 1.4 (0.8–2.6) 0.3
Selectin ≤ 53 4 6 (17.1) 16 (44.4) 0.6 (0.3–1.2) 0.14
Adiponectin ≤ 11 8 15 (42.9) 17 (47.2) 0.8 (0.5–1.2) 0.4
Data expressed as n (%) and relative risk (95%CI). ∗Relative risk adjusted for baseline values of the inflammatory markers.
Table 4: Frequency of adverse events in each treatment group.
Adverse events Diacerein (n = 35) Placebo (n = 36) P
Nausea 6 (17.1) 3 (8.3) 0.3
Vomiting 1 (2.9) 4 (11.1) 0.2
Diarrhea 10 (28.6) 6 (16.7) 0.2
Abdominal pain 4 (11.4) 4 (11.1) 1.0
Dark urine 21 (7.4) 8 (2.9) 0.001
Others 5 (14.3) 0 0.03

































Diabetes mellitus duration: 14−30 years




Figure 2: End-of-trial changes in HbA1c (%) in the diacerein and placebo groups, stratified by duration of diabetes< 14 (a) or ≥14 years (b),
independently of age and gender.
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IL-1β levels. Villar et al. [10] evaluated 12 patients receiving
metformin as monotherapy and found a significant improve-
ment of glycemic control, with reduction of HbA1c and
glucose levels. Cardoso et al. [11] selected 84 patients aged
less than 75 years, receiving full glucose-lowering treatment,
who were randomized to diacerein or placebo with 48 weeks
of follow-up. The diacerein group had a 0.35% reduction in
HbA1c compared to the placebo group at week 24 of treat-
ment, but this effect was attenuated to a nonsignificant
difference at week 48. Participants had a median disease
duration of 10 years (interquartile range: 6–18 years). The
results of these trials point in the same direction, that is, a
reduction in HbA1c in patients who receive diacerein. How-
ever, there are striking differences between the present trial
and those of Ramos-Zavala and Cardoso, both of which
selected patients who were receiving no treatment for diabe-
tes or only monotherapy. Our trial is more similar to that of
Cardoso et al. [11]. However, we enrolled patients up to 79
years of age and with longer duration of diabetes and
followed participants for a longer time. These differences
raised the need to evaluate the effect of diacerein by taking
into account the duration of diabetes, which was done in an
exploratory analysis.
The reduction in HbA1c levels was not followed by a
reduction in HOMA-IR levels, suggesting that the effect of
diacerein may have been on insulin secretion. Studies have
shown that T2DM is an inflammatory disease. Adipose
tissue appears to play a central role in the induction of
inflammation, leading to the production of proinflammatory
cytokines, particularly TNF-α and IL-1β. These cytokines
induce β-cell dysfunction, with subsequent apoptosis and
insulin deficiency [4]. However, few controlled studies have
tested drugs that play a role in the inhibition of proinflamma-
tory cytokines and their receptors in patients with T2DM.
Drugs with anti-inflammatory action may be more effective
in the early stages of the disease, when functional impairment
of pancreatic β-cells is less severe, with a better chance of
regaining their function, thus contributing to the main effect
of lowering HbA1c levels among those with a shorter dura-
tion of diabetes. Malaguti et al. [13], in an experimental
study, tested diacerein in nonobese diabetic mice aiming to
investigate anti-inflammatory properties and their potential
effects on type 1 diabetes. The results showed that diacerein,
via modulation of proinflammatory cytokines (IL-1β and
TNF-α), interferes with the onset of type 1 diabetes and
may alter the incidence of autoimmune diabetes in treated
animals. These findings are consistent with the reduced
TNF-α observed in this study of T2DM patients. Although
autoimmune mediators are not typical of this condition,
inflammation may potentially lead to β-cell apoptosis.
Another experimental study in obese mice suggests that
diacerein may be a potential alternative treatment to reverse
or improve clinical features of obesity-related T2DM and
insulin resistance [14].
The present study has some limitations that should be
noted. The size of the sample and the relatively short
duration of the intervention, considering the long-standing
nature of T2DM, precluded assessment of the long-term
efficacy and safety of diacerein. In addition, our findings do
not allow us to draw any conclusion about the effects of
diacerein among patients with poor metabolic control, since
patients with HbA1c ≥ 11 0% (97mmol/mol) were excluded.
Finally, the effect on the subgroup with shorter duration
of diabetes should be viewed with caution, as this was a
post hoc analysis.
In conclusion, diacerein therapy in patients with long-
established T2DM and long-term use of glucose-lowering
agents improves metabolic control as measured by HbA1c
level and has a favorable impact on the inflammatory profile.
Thus, the use of diacerein may be beneficial in counteracting
the adverse consequences of diabetes. However, further
studies with a larger sample size, including participants
exposed to diacerein with shorter and longer duration of
diabetes, are needed to confirm these findings.
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